A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

DermTech500 enrolled

Overview

This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic dermatitis. Samples collected will be analyzed to detect gene signatures and microbiome populations associated with atopic dermatitis and sub-populations of AD. Approximately 500 pediatric and adult subjects with moderate to severe AD will be enrolled in this study. Non-invasive skin samples will be collected at baseline, before drug administration 16 weeks (+/- 2 weeks) after treatment with biological therapy and a final visit at 26 weeks ((+/- 4 weeks). Subjects will enter the Screening Period once the informed consent and/or assent process has been completed. Once patient eligibility is confirmed, non-invasive skin samples will be collected using DermTech's non-invasive sample collection kit. Samples will be collected from the following areas: * Target Lesion - lesional skin for genomic analysis. Please note the location for subsequent collections. * Lesional skin for microbiome analysis similar in size and severity to the target lesion noted above. Please note the location for subsequent collections. * Non-lesional skin at least 5 cm from any active lesion. The intervals for subsequent sample collection, if applicable, will be determined based on standard of care (SOC) treatment and the subject's willingness to undergo repeat non-invasive sampling. Data to be collected includes eczema area and severity index (EASI), patient oriented eczema measure (POEM), investigator global assessment (IGA), peak pruritus numerical rating scale (PPNRS), and transepidermal water loss (TEWL). Photographic documentation of the site(s) sampled should be obtained to confirm consistent sampling of the lesional and non-lesional sites. Each non-invasive sample collection will consist of sequential application of 4 individual patches to a site. If during active treatment the skin lesion disappears during active treatment, skin samples will still be obtained from the same location.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Atopic Dermatitis

Interventions

Biologic therapy versus no biologic therapyOTHER

Biologic therapy administered per standard of care

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

Inclusion Criteria: 1. Males and females at least 1 year of age; 2. Subjects with documented, active moderate to severe atopic dermatitis; 3. Subjects must have a history of atopic dermatitis for at least three months; 4. Subjects with no known reactions to adhesives; 5. Subject has a sufficient number of target plaques on the central body, which includes knees or elbows, and not limited to lesions on the mucosal membranes, soles of the feet or palms of the hands; 6. Subjects willing to follow standard of care (SOC) for his/her atopic dermatitis; and 7. Subjects must be able to complete all study visits required by the protocol. Exclusion Criteria: 1. Pregnant or breast feeding, including positive pregnancy test at baseline or expected to become pregnant during participation in the trial; 2. History of cancer (exceptions for: a) non-metastatic malignancy deemed cured at the time of enrollment, b) skin cancer that has been excised with controlled margins or has not recurred in 6 months; and c) treated cervical cancer in situ); 3. Current acute infectious illness (viral, parasitic or bacterial) within 4 weeks of enrollment; 4. Receipt of systemic anti-atopic dermatitis medication, including retinoids, corticosteroids, cyclosporine, methotrexate within the four weeks of the Baseline Visit; 5. Use of topical therapy (except emollients) for atopic dermatitis or any other condition within two weeks of the Baseline Visit; 6. Receipt of any investigational drug therapy within four weeks or 5 half-lives, whichever is longer of study enrollment, or concurrent participation in another interventional clinical study; and 7. Documented substance abuse, any other significant medical condition or laboratory result that would indicate an unreasonable risk to the subject or potential interference with study procedures, or would negatively affect the patient's reliability and compliance with the study schedule.

Locations (2)

Orit Markowitz

New York, New York, United States

RECRUITING

Lisa A. Beck

Rochester, New York, United States

RECRUITING

Outcomes

Primary Outcomes

Gene expression with primary disease assessment EASI

Expression of genes with disease activity measures including the EASI score

Time frame: Week 16

Secondary Outcomes

Gene expression correlated with POEM assessment

Expression of genes in the DermTech assay with POEM disease activity

Time frame: Week 16

Gene expression correlated with IGA assessment

Expression of genes in the DermTech assay with IGA disease activity

Time frame: Week 16

Gene expression correlated with TEWL assessment

Expression of genes in the DermTech assay with TEWL

Time frame: Week 16

Gene expression correlated with PRNS assessment

Expression of genes in the DermTech asssay with PPRNS

Time frame: Week 16

Central Contacts

James Rock

CONTACT

18582052736 jrock@dermtech.com

Susan Huynh

CONTACT

8584504222 susan.huynh@dermtech.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.